Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
NCT ID: NCT03260179
Last Updated: 2017-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
60 participants
INTERVENTIONAL
2017-08-31
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
NCT04615312
A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors
NCT02825940
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer
NCT01291407
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
NCT04358341
A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
NCT02096666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
gastric carcinoma
20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
AL3810
Fasting，oral ，4w on or 3w on/1w off
hepatocellular carcinoma
20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
AL3810
Fasting，oral ，4w on or 3w on/1w off
Nasopharyngeal carcinoma
20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
AL3810
Fasting，oral ，4w on or 3w on/1w off
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AL3810
Fasting，oral ，4w on or 3w on/1w off
AL3810
Fasting，oral ，4w on or 3w on/1w off
AL3810
Fasting，oral ，4w on or 3w on/1w off
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Life expectancy ≥ 12 weeks as judged by the Investigator.
3. Histologically or cytologically confirmed, locally advanced or metastatic solid tumor and be limited to:
* Gastric carcinoma (including gastro-oesophageal junction adenocarcinoma).
* Hepatocellular carcinoma (Child-Pugh Class A).
* Undifferentiated nasopharyngeal carcinoma.
4. Each subject should provide at least 5 slides for the formalin fixed and paraffin embedded tumor biopsy (undyed) at the baseline, fresh biopsy or most recent primary tumor sample or metastatic sample is required.
5. Patients, who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists.
6. Toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤ 1 as per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), excluding alopecia and peripheral neuropathy. For subjects having a prior platinum-based therapy, peripheral neuropathy are required to recover to ≤ CTCAE grade 2.
7. Per RECIST v1.1 guidelines for solid tumors:
* Patients with gastric carcinoma should have at least one measurable lesion beyond stomach,
* Patients with Hepatocellular carcinoma and undifferentiated nasopharyngeal carcinoma should have at least one measurable lesion.
8. Adequate bone marrow and organ function as defined by the following laboratory values: (prophylactic use of myeloid growth factors (eg, G-CSF, GM-CSF) is prohibited within 2 weeks before screening)
* Absolute neutrophil count (ANC) ≥ 1.5x 109/L.
* Platelet counts ≥ 100 x 109/L.
* Haemoglobin ≥ 90 g/L (without blood transfusion within the last 2 weeks from screening).
* Creatinine clearance \> 50 mL/min (calculated according to Cockroft-Gault formula).
* Proteinuria \< 1+. If proteinuria ≥ 1+, urine protein quantitation over 24 hours should be \< 1.0 g/24hrs.
* INR ≤ 1.5 and APTT≤ 1.5 Upper Limit of Normal (ULN).
* AST, ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases or hepatocellular carcinomas are present).
* Total Bilirubin \< 1.5 x ULN.
* For Hepatocellular carcinomas patients, albumin ≥ 28 g/dL.
9. Patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1.
10. Patient is able to swallow and retain oral medication.
11. Female subjects, with childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration). The definition of women with child-bearing potential are defined as "All female subjects after puberty unless they are post-menopausal or not sexually active". Females are considered postmenopausal if they have age-related amenorrhea ≥ 12 consecutive months or if they have undergone hysterectomy or bilateral oophorectomy.
12. Patients who have fully understood the study, and have signed the general Informed Consent Form (ICF) prior to any screening procedures being performed
Main criteria for non-inclusion
1. Patient who has participated in another interventional trial within 28 days prior to starting study medicine. If a subject is joining a non-interventional trial, such as an epidemiological study, or in a survival follow-up period of an interventional trial, he or she may participate in this trial.
2. Expected poor compliance during the study.
3. Patient has symptomatic CNS metastases requiring clinical intervention. The stable patient may participate in this trial, who must have completed any prior local treatment for CNS metastases ≥ 14 days prior to the start of study treatment (including radiotherapy and/or low dose steroid therapy).
4. Patient has a concurrent malignancy or malignancy within 2 years of study enrolment, with the exception of adequately treated and cured non-melanomatous skin cancer, carcinoma in situ of breast and cervix, and superficial bladder cancer.
5. Patient who has received chemotherapy, targeted therapy or immunotherapy within 28 days or ≤ 5 half-lives prior to starting study medicine. Take the longer one. For HCC patient who has received any prior local therapy (hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) within 4 weeks of starting study medicine •.
6. Previous treatment with Bevacizumab within 3 months of starting AL3810. In addition:
\- Patients with nasopharyngeal carcinoma who received antiangiogenic agent are not allowed.
7. Patients with nasopharyngeal carcinoma located within 5mm of large blood vessels.
8. Patient who has received wide field radiotherapy within 28 days prior to starting study medicine
9. Patient who has received a major surgery within 28 days prior to starting study medicine. The definition of a major surgery refers to grade 3 and 4 surgery specified in \<Management of Clinical Practice of Medical Technologies\> effective on May 1, 2009 in China,
10. Patient has active cardiac disease or a history of cardiac dysfunction in screening including any of the following:
* History of documented Congestive heart failure ≥ class II (NYHA New York Heart Association functional classification) or requiring therapy,
* Ventricular and/or supraventricular arrhythmia requiring therapy;
* Severe conduction disturbance (including QTc interval prolongation \> 450msec \[corrected by Fredericia formula\], history of severe arrhythmia, or history of familial arrhythmia \[e.g., Wolff-Parkinson-White syndrome\]),
* Angina pectoris requiring therapy,
* Left ventricular ejection fraction (LVEF) \< 50% evaluated by cardiac ultrasound (ECHO) or Multi Gated Acquisition Scan (MUGA) ,
* Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg with optimized antihypertensive therapy or patients treated with ≥ 2 antihypertensive agents),
* Hypertension with systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 100mmHg with or without antihypertensive therapy.
* Conduction abnormality requiring a pacemaker or implanted a pacemaker.
11. History of clinically significant or uncontrolled cardiac disease within 6 months prior to starting AL3810, including angina, myocardial infarction, and stroke.
12. Patients with thromboembolic events within 12 months prior to starting AL3810, or at a high risk of such events.
13. Patient with hereditary risks of thromboembolic events.
14. Patient is currently receiving treatment with warfarin or any other oral Anticoagulants
15. Patients with active HBV or HCV infection or known positivity for human immunodeficiency virus (HIV) infection are not allowed. HBV, HCV and HIV will be tested in the screening. Serum HBsAg positive with HBV DNA \<104 Copy/mL may participate study. Prophylactic anti-HBV medications application can be accepted. Serum HCV or HIV antibody positive is not allowed.
16. Patients receiving medications known to prolong QTc interval and that may be associated with Torsades de Pointes.
17. Serum potassium (K+) levels below LLN at screening period.
18. Patients who received administration of strong inhibitors of CYP2C8 and/or CYP3A4 or strong inducers of CYP3A4 within 7 days or ≤ 5 half-lives (Take the longer one) prior to starting AL3810. And patient cannot stop taking the medication. .
19. Significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhoea associated with intestinal malabsorption, the Crohn's disease, or significant abnormalities decided by investigator. In addition, patients with any grade of gastro-intestinal bleeding events within 3 months prior to starting AL3810 are not allowed.
20. History of grade 3 haemorrhage/bleeding events within 6 months prior to starting AL3810, or history of grade 4 haemorrhage/bleeding events.
21. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, thyroid and adrenal gland.
22. Serious/active bacterial, viral or fungal infection requiring systemic treatment.
23. Concomitant uncontrolled severe systemic disease (e.g., uncontrolled diabetes mellitus, uncontrolled ascites, etc.).
24. Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study procedures.
25. Known organ dysfunction which would either compromise the patient's safety or interfere with the evaluation of AL3810.
26. Male patients and female patients of child bearing potential unable or unwilling to employ effective contraception (abstinence, barrier method with spermicide, intrauterine device, or steroidal contraceptive for women and barrier method) during the study and for 6 months thereafter.
27. Breastfeeding women.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
OTHER
Haihe Biopharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The 307th Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Sun Yat-sen University
Guangzhou, Guangdong, China
The 81st Hospital of People's Liberation Army
Nanjing, Jiangsu, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Sun Yat-sen University Cancer Center
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xu Jian ming, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Zhang Y, Luo F, Ma YX, Liu QW, Yang YP, Fang WF, Huang Y, Zhou T, Li J, Pan HM, Yang L, Qin SK, Zhao HY, Zhang L. A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. Oncologist. 2022 Jun 8;27(6):e453-e462. doi: 10.1093/oncolo/oyab076.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL1-80881-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.